(0.06%) 5 472.55 points
(0.08%) 39 143 points
(0.37%) 17 784 points
(-0.02%) $80.81
(-3.66%) $2.66
(-0.76%) $2 313.20
(0.25%) $28.94
(3.64%) $1 022.30
(0.26%) $0.936
(0.68%) $10.68
(0.46%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs...
Stats | |
---|---|
今日成交量 | 516 |
平均成交量 | 6 162 |
市值 | 22.55M |
EPS | $-2.83 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $-3.03 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.620 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Kisner Daniel L | Buy | 2 200 | Stock Options |
2024-06-20 | Carter Michael G | Buy | 2 200 | Stock Options |
2024-06-20 | Wills Robert James | Buy | 2 200 | Stock Options |
2024-06-20 | Larue William R | Buy | 2 200 | Stock Options |
2024-06-20 | Hale David F | Buy | 3 300 | Stock Options |
INSIDER POWER |
---|
18.28 |
Last 100 transactions |
Buy: 5 653 801 | Sell: 3 918 128 |
Oncternal Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Oncternal Therapeutics 财务报表
Annual | 2023 |
营收: | $785 000 |
毛利润: | $-28.97M (-3 690.19 %) |
EPS: | $-13.43 |
FY | 2023 |
营收: | $785 000 |
毛利润: | $-28.97M (-3 690.19 %) |
EPS: | $-13.43 |
FY | 2022 |
营收: | $1.49M |
毛利润: | $1.31M (87.99 %) |
EPS: | $-16.50 |
FY | 2021 |
营收: | $4.32M |
毛利润: | $4.32M (100.00 %) |
EPS: | $-0.640 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oncternal Therapeutics
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。